You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

exon L858R

Showing 1 - 25 of 963
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC, Bevacizumab, EGF-R Positive NSCLC Trial in Tianjin (Bevacizumab, Icotinib)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +3 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Mar 2, 2022

Lung Cancer Trial in Guangzhou (Osimertinib, Bevacizumab)

Not yet recruiting
  • Lung Cancer
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Jul 26, 2021

Lung Tumor, NSCLC, Respiratory Tract Tumors Trial in United States (BLU-701, osimertinib, carboplatin)

Recruiting
  • Lung Neoplasm
  • +26 more
  • Boston, Massachusetts
  • +6 more
Jun 23, 2022

NSCLC With Mutation in Epidermal Growth Factor Receptor Trial in Kunming (Combined therapy of anlotinib and aumolertinib)

Recruiting
  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
  • Combined therapy of anlotinib and aumolertinib
  • Kunming, Yunnan, China
    First Affiliated Hospital of Kunming University
Oct 22, 2023

Non Small Cell Lung Cancer, EGFR Activating Mutation, EGFR DEL19 Trial in France (Plasma ctDNA, FFPE blocks)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • Plasma ctDNA
  • FFPE blocks
  • Angers, France
  • +35 more
Sep 19, 2023

NSCLC (NSCLC) Trial (Dacomitinib+Anlotinib, Dacomitinib)

Not yet recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • (no location specified)
Feb 28, 2022

Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Worldwide (BLU-945, osimertinib)

Recruiting
  • Lung Neoplasms
  • +23 more
  • La Jolla, California
  • +35 more
Oct 6, 2022

NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Santa Monica, California
  • +13 more
Feb 1, 2023

NSCLC Trial in Worldwide (Lazertinib, Amivantamab, Pemetrexed)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Phoenix, Arizona
  • +303 more
Aug 17, 2022

NSCLC Trial in Worldwide (Amivantamab, Osimertinib, Lazertinib)

Active, not recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Goodyear, Arizona
  • +266 more
Aug 17, 2022

NSCLC, ErbB Receptors Trial in United States (Afatinib)

Completed
Has Results
  • Carcinoma, Non-Small-Cell Lung
  • ErbB Receptors
  • Scottsdale, Arizona
  • +9 more
Mar 16, 2020

Non Small Cell Lung Cancer Trial in Durham (Atezolizumab, Bevacizumab)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • Durham, North Carolina
    Duke University Medical Center
May 23, 2022

NSCLC Trial in Worldwide (PF-06747775, Palbociclib, Avelumab)

Terminated
Has Results
  • Non-Small Cell Lung Cancer
  • La Jolla, California
  • +14 more
May 13, 2021

PFS Trial in Shanghai (Gefitinib, Bevacizumab Combined With Gefitinib)

Recruiting
  • PFS
  • Shanghai, Shanghai, China
    Cancer hospital Fudan University
Jun 10, 2020

NSCLC Stage IV, EGFR Gene Mutation Trial in Worldwide (Osimertinib, Stereotactic Body Radiation Therapy (SBRT))

Recruiting
  • NSCLC Stage IV
  • EGFR Gene Mutation
  • Alessandria, Italy
  • +15 more
Mar 29, 2022

Osimertinib for NSCLC With Uncommon EGFR Mutations

Enrolling by invitation
  • Carcinoma, Non-Small-Cell Lung
  • Genes, erbB-1
  • Ramat Gan, Israel
    Sheba Medical Centre
Jun 14, 2022

NSCLC Trial (Idylla EGFR_IUO/3.20 Mutation Test)

Not yet recruiting
  • NSCLC
  • Idylla EGFR_IUO/3.20 Mutation Test
  • (no location specified)
Jul 24, 2023

Carcinoma, Non-small-Cell Lung Trial in Worldwide (Amivantamab, Lazertinib, Carboplatin)

Not yet recruiting
  • Carcinoma, Non-small-Cell Lung
  • Westwood, Kansas
  • +47 more
Aug 17, 2022

NSCLC (NSCLC) Trial in China (Capmatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Xiamen, Fujian, China
  • +18 more
Jan 27, 2023

NSCLC Trial (Recombinant anti-VEGFR2 fully human mAb (JY025))

Not yet recruiting
  • NSCLC
  • Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)
  • (no location specified)
May 7, 2021

Non Small Cell Lung Cancer Trial in Seoul (Lazertinib+Pemetrexed+Carboplatin, Lazertinib)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Aug 31, 2023

NSCLC (NSCLC) Trial (MK-2870, Docetaxel, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • MK-2870
  • +2 more
  • (no location specified)
Oct 3, 2023

Double-dose Furmonertinib in Treatment of Slow

Not yet recruiting
  • Non Small Cell Lung Cancer
  • +3 more
  • (no location specified)
Oct 31, 2023

EGFR Exon 19 Deletion Mutation, EGFR NP_005219.2:p.L858R, Lung Non-Squamous Non-Small Cell Carcinoma Trial in United States

Completed
Has Results
  • EGFR Exon 19 Deletion Mutation
  • +3 more
  • Bevacizumab
  • +3 more
  • La Jolla, California
  • +18 more
Sep 16, 2020

Non Small Cell Lung Cancer, CNS Progression Trial in Aurora (Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib)

Active, not recruiting
  • Non Small Cell Lung Cancer
  • CNS Progression
  • Temozolomide plus Osimertinib
  • Temozolomide plus Lorlatinib
  • Aurora, Colorado
    University of Colorado Hospital
May 12, 2022